Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis

Abstract Background Treatment of heart failure with reduced ejection fraction (HFrEF) has been revolutionized by angiotensin receptor/neprilysin inhibitor (ARNI). ARNI has been shown to significantly reduce morbidity and mortality in a large, randomized controlled trial. However, real-world evaluati...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Wipharak Rattanavipanon, Thanyaluck Sotananusak, Fairus Yamaae, Arisa Chandrsawang, Pitchapa Kaewkan, Surakit Nathisuwan, Teerapat Yingchoncharoen
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2021-07-01
Ráidu:	BMC Cardiovascular Disorders
Fáttát:	Heart failure Sacubitril Valsartan Angiotensin receptor Neprilysin inhibitor
Liŋkkat:	https://doi.org/10.1186/s12872-021-02145-9
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!